SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

November 10, 2010 16:05 ET

SciClone Pharmaceuticals to Present at Two Investor Conferences in November

Lazard Capital Markets Healthcare Conference on November 16 at 2:40 pm ET; Piper Jaffray Health Care Conference on November 30 at 12:30 pm ET

FOSTER CITY, CA--(Marketwire - November 10, 2010) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at two upcoming investor conferences: Lazard Capital Markets Healthcare Conference and Piper Jaffray Health Care Conference. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update at each conference.

Lazard Capital Markets Healthcare
Tuesday, November 16; 2:40 pm ET
New York City, NY

Piper Jaffray Health Care Conference
Tuesday, November 30; 12:30 pm ET
New York City, NY

To access the live audio webcasts of the presentations, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com

About SciClone
SciClone Pharmaceuticals (NASDAQ: SCLN) is a revenue-generating, China-centric, specialty pharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. The Company is focused on continuing sales growth and executing a clinical development strategy with prudently managed costs. ZADAXIN® (thymalfasin) is approved in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers, and as a vaccine adjuvant. In addition to further studying thymalfasin's use as a vaccine enhancer, SciClone is planning to evaluate SCV-07 in a phase 2b trial to modify the course of oral mucositis in patients with head and neck cancer; and is evaluating SCV-07 in a phase 2b trial for the treatment of HCV. The Company also has exclusive commercialization and distribution rights in China to a novel treatment for advanced liver cancer, DC Bead®, currently under review by regulatory agencies in that country. Additionally, SciClone owns exclusive commercialization and distribution rights to the anti-nausea drug ondansetron RapidFilm® in China, including Hong Kong and Macau, and Vietnam. The Company intends to seek regulatory approval for the product, commonly used to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery, in these markets. For additional information, please visit www.sciclone.com.

DC Bead is a registered trademark of Biocompatibles UK Limited.

RapidFilm is a registered trademark of Labtec Gesellschaft für technologische Forschung und Entwicklung mbH.